Full-Time

Vice President

Medical Affairs

Confirmed live in the last 24 hours

Delfi Diagnostics

Delfi Diagnostics

51-200 employees

Advanced cancer detection using DNA analysis

Compensation Overview

$330k - $387k/yr

Expert

Remote in USA

Candidates must be based within 50 miles of Palo Alto, CA or Baltimore, MD for in-office days.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Delfi Diagnostics referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • M.D. or D.O. (Doctor of Osteopathy)
  • Minimum of 12 years of experience in medical affairs, with at least 5 years in a leadership role within a biotechnology, diagnostics, or pharmaceutical company
  • Proven track record of leading cross-functional teams, integrating scientific data into commercial, regulatory, and strategic objectives
  • Extensive experience in creating and overseeing clinical content for both promotional and educational materials
  • Experience leading clinical interactions with key stakeholders, including commercial teams, advocacy groups, and government agencies
  • Expertise in managing multiple projects, from concept to execution, ensuring timelines, budgets, and quality standards are met
  • Strong experience working with advocacy groups, government affairs, and external stakeholders to shape scientific policy and business strategies
  • Exceptional leadership, communication, and interpersonal skills, with the ability to engage with both scientific and non-scientific audiences
  • Strong ability to navigate complex and fast-paced environments and drive results across multiple organizational functions
Responsibilities
  • Lead and develop the Medical Sciences Liaison team, creating a culture focused on scientific excellence and customer-centered solutions
  • Implement and enhance the comprehensive medical affairs strategy to address both the clinical interests and needs of key stakeholders, both internal and external to DELFI
  • Provide meaningful input to DELFI’s portfolio strategy and long term plan by translating technology and product strengths to unmet medical needs with high clinical utility for DELFI’s approach
  • Develop timelines, budgets, and resource plans for key medical affairs initiatives including KOL engagement, guideline oriented evidence and communication planning, medical education programs, and investigator led studies. Ensure that these initiatives are efficiently executed and aligned with corporate milestones
  • Partner with and provide clinical insights to the commercial, clinical development, research and regulatory teams to drive the company's key objectives
  • Create and foster close working relationships with advocacy groups, healthcare providers, and policymakers to support DELFI’s mission and unique clinical and testing platform proposition
  • Work closely with Clinical Development and Medical Evidence teams to generate high-quality clinical data and evidence, including real-world data that support DELFI Diagnostics’ products and technologies
  • Work with the Clinical Development leadership to ensure all clinical studies are designed to generate evidence that informs regulatory submissions, reimbursement strategies, and market access
  • Provide clinical guidance on the interpretation of clinical data and ensure the translation of scientific findings into meaningful insights that support the company’s objectives
  • Develop and implement strategy for investigator initiated research employing DELFI technology
  • Operationally oversee the creation, review, and approval process for all medical content, ensuring it meets scientific, regulatory, and legal standards. This includes everything from promotional materials to scientific publications and educational content
  • Be accountable for clinical content in all promotional and educational materials and related activities, ensuring scientific integrity and alignment with regulatory standards
  • Serve as the primary clinical lead for all external interactions, including with commercial teams, advocacy groups, and government stakeholders
  • Contribute to the development of communication and messaging strategies for clinical products, ensuring that the company’s clinical assets are effectively represented
  • Position KOLs (Key Opinion Leaders) for presentations at scientific forums, including national and regional specialty society meetings, grand rounds, and continuing medical education (CME) events at targeted institutions
  • Identify and execute strategies and tactics for engagement with key influencers in the medical and advocacy communities, ensuring strong relationships and alignment with the company’s goals
  • Drive the implementation of multi-party demonstration efforts, aligning with company objectives and supporting evidence-based initiatives
  • Develop and monitor key performance indicators (KPIs) to measure the effectiveness of medical affairs initiatives and ensure that the goals are being met on schedule, which includes managing operational challenges and ensuring that projects stay on track

Delfi Diagnostics focuses on early cancer detection using advanced machine learning and fragmentomics, which involves analyzing fragments of cell-free DNA. Their technology differs from traditional methods by scanning millions of data points to find previously unrecognized cancer-associated fragments, allowing for a more comprehensive detection of cancer. The company is led by a team of experts in cancer biology, bioinformatics, and machine learning, with Dr. Victor Velculescu as the CEO, who is well-known in the field of genomics. Delfi Diagnostics aims to provide healthcare providers and patients with effective cancer detection services, positioning itself as a leader in healthcare technology.

Company Size

51-200

Company Stage

Series B

Total Funding

$330.5M

Headquarters

Baltimore, Maryland

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent AI advancements enhance the sensitivity of Delfi's fragmentomics-based cancer detection.
  • Partnerships with biotech firms expand Delfi's technology applications and market reach.
  • Merck's investment accelerates Delfi's genomic technology development and R&D capabilities.

What critics are saying

  • Competition from City of Hope's blood test may capture Delfi's market share.
  • Over-reliance on partnerships could pose risks if collaborations don't yield expected results.
  • New executive appointments may lead to strategic shifts or internal disruptions.

What makes Delfi Diagnostics unique

  • Delfi Diagnostics uses fragmentomics for early cancer detection, unlike traditional mutation-focused methods.
  • The company integrates AI with genome-wide fragmentomics for high sensitivity in cancer screening.
  • Delfi's team includes experts in genomics, bioinformatics, and regulated software development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Parental Leave

Flexible Time Off

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

0%

2 year growth

4%
PR Newswire
Apr 25th, 2025
Delfi Diagnostics To Present Early Detection And Advanced Cancer Monitoring Technology Updates At Aacr Annual Meeting

Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research eventBALTIMORE and PALO ALTO, Calif., April 25, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc ., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced its team is presenting at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. DELFI is showcasing its groundbreaking DELFI-TF technology for treatment response monitoring alongside its early detection capabilities."Our presentations at AACR highlight how DELFI's fragmentomics platform is transforming both early cancer detection and treatment monitoring," said Victor E. Velculescu, MD, PhD, DELFI Diagnostics Founder and Board Director. "The DELFI technology represents a paradigm shift in how we detect cancer by combining genome-wide fragmentomics of DNA in the blood with AI algorithms for high sensitivity in the screening setting as well as for noninvasively measuring treatment efficacy in advanced cancer patients. "DELFI is presenting multiple podium and poster sessions at AACR, including:Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection presented by Victor E. Velculescu, MD, PhDTuesday, April 29 , 11:06 AM - 11:26 AM CT, Room S100 BC (Grand Ballroom BC) - McCormick Place SouthLeveraging the cfDNA fragmentome to predict immunotherapy response presented by Valsamo Anagnostou, MD, PhDMonday, April 28 , 3:05 PM - 3:20 PM CT, Room S105 - McCormick Place SouthAnalysis of lung cancer clinical characteristics using cell-free DNA fragmentomes presented by Lorenzo Rinaldi, PhDMonday, April 28 , 9:00 AM - 12:00 PM CT, Section 28, Poster 29Cell-free DNA fragmentomes for treatment response monitoring in patients with metastatic colorectal cancer: the DOLPHIN study presented by Denise E

Bizjournals
Oct 30th, 2024
8 things to know: New Under Armour HQ almost complete

Canton-based Delfi Diagnostics has named Robert Guigley as its new chief commercial officer.

PR Newswire
Oct 28th, 2024
DELFI Diagnostics Working with Incendia Therapeutics to Employ Advanced Treatment Monitoring Test in a Phase 1 Clinical Trial

DELFI Diagnostics working with Incendia Therapeutics to employ advanced treatment monitoring test in a Phase 1 clinical trial.

PR Newswire
Aug 26th, 2024
DELFI Diagnostics Appoints Thomas Russo as Chief Financial Officer

DELFI Diagnostics appoints Thomas Russo as Chief Financial Officer.

Finsmes
Jun 5th, 2024
DELFI Diagnostics Receives Equity Investment From Merck Global Health Innovation Fund

DELFI Diagnostics receives equity investment from Merck Global Health Innovation Fund.